{"artifact":{"id":"experiment-exp-fe270634-6727-428d-b105-0f09d0bf86f2","artifact_type":"experiment","entity_ids":"[]","title":"Tirzepatide vs Semaglutide Anti-Atherosclerotic Effects in ApoE KO Mice","quality_score":0.9,"created_by":"experiment_extractor","provenance_chain":"[]","content_hash":"0da290f271a52c52da6a0bfbb286ab6abcb913e33ab7b8e91a666183eaaff9f6","metadata":{"_origin":{"url":null,"type":"internal","tracked_at":"2026-04-10T22:43:24.108122"},"p_value":null,"protocol":"ApoE knockout mice were treated with streptozotocin to induce diabetes, then divided into three groups (early diabetes 10-22 weeks, late diabetes 18-30 weeks, non-diabetic). Each group received 12 weeks of treatment with tirzepatide, semaglutide, or saline control. Assessments included plaque quantification, glycemic measurements, lipid profiling, and inflammatory marker analysis.","effect_size":null,"sample_size":null,"source_pmid":"41946762","extracted_at":"2026-04-10T15:43:24.105488","_schema_version":1,"experiment_type":"animal_model","success_criteria":"Significant reduction in aortic plaque formation compared to saline control, improvement in glycemic and lipid parameters, and reduction in inflammatory mediators","expected_outcomes":"Both tirzepatide and semaglutide were expected to reduce atherosclerotic plaque formation and improve metabolic parameters, with potential differences in their anti-inflammatory profiles","statistical_methods":null},"created_at":"2026-04-10T22:43:24-07:00","updated_at":"2026-04-10T22:43:24-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"internal","origin_url":null,"lifecycle_changed_at":"2026-04-10T22:43:24-07:00","citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":"ok","contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"10837b9f-ab0f-49fc-a242-c2c5e72a4a81","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"experiment_extractor"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[{"target_artifact_id":"wiki-therapeutics-glp1-agonists-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-mechanisms-glp1-receptor-agonists-parkinsons","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-proteins-glp-1-receptor","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-gaps-glp-1-responder-biology-parkinsons","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-therapeutics-glp1-receptor-agonists-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-mechanisms-glp-1-signaling-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-experiments-glp1-agonist-pd-mechanism","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-therapeutics-gip-glp1-dual-agonists-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GIP"},{"target_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-clinical-trials-nct07083154","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-investment-glp1-receptor-agonists","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-investment-glp-1-therapeutics","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-experiments-glp1-responder-prediction-pd","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-entities-glp1-receptor","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists-parkinsons","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-therapeutics-glp1-gip-agonists-neurodegeneration","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"},{"target_artifact_id":"wiki-ideas-payload-glp1-receptor-agonist-therapy","link_type":"related","strength":0.63,"evidence":"Reverse: Gene mention: GLP"}],"incoming_links":[{"source_artifact_id":"wiki-therapeutics-glp1-agonists-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-mechanisms-glp1-receptor-agonists-parkinsons","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-proteins-glp-1-receptor","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-gaps-glp-1-responder-biology-parkinsons","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-therapeutics-glp1-receptor-agonists-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-mechanisms-glp-1-signaling-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-experiments-glp1-agonist-pd-mechanism","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-therapeutics-gip-glp1-dual-agonists-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GIP"},{"source_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-clinical-trials-nct07083154","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-investment-glp1-receptor-agonists","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-investment-glp-1-therapeutics","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-experiments-glp1-responder-prediction-pd","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-entities-glp1-receptor","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-therapeutics-glp-1-receptor-agonists-parkinsons","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-therapeutics-glp1-gip-agonists-neurodegeneration","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"},{"source_artifact_id":"wiki-ideas-payload-glp1-receptor-agonist-therapy","link_type":"mentions","strength":0.7,"evidence":"Gene mention: GLP"}],"current_artifact_id":"experiment-exp-fe270634-6727-428d-b105-0f09d0bf86f2","is_canonical":true,"supersede_chain":["experiment-exp-fe270634-6727-428d-b105-0f09d0bf86f2"]}